VBI Vaccines is a technology company.
VBI Vaccines has raised $36.0M across 1 funding round.
VBI Vaccines has raised $36.0M in total across 1 funding round.
VBI Vaccines has raised $36.0M in total across 1 funding round.
VBI Vaccines's investors include 5AM Ventures, ARCH Venture Partners.
VBI Vaccines Inc. (VBIV) is a biopharmaceutical company developing innovative vaccine and immunotherapeutic candidates using proprietary enveloped virus-like particle (eVLP) and mRNA-launched eVLP (MLE) platform technologies to prevent and treat infectious diseases and cancers.[1][2][3] Its flagship product, PreHevbrio (known as Sci-B-Vac in some markets), is the only approved 3-antigen hepatitis B vaccine targeting Pre-S1, Pre-S2, and S antigens, serving adults at risk of hepatitis B infection and approved in the U.S., EU/EEA, UK, Canada, and Israel.[1][2][3][5] The company addresses unmet needs in underserved markets by mimicking natural virus structures for robust immune responses and incorporating thermostable formulations to overcome cold-chain logistics challenges, with a pipeline including candidates for cytomegalovirus (CMV), coronaviruses, chronic hepatitis B (VBI-2601), and glioblastoma (VBI-1901).[1][2][3][5] Growth momentum includes U.S. FDA approval of PreHevbrio in 2021, ongoing clinical advancements, and collaborations with partners like Brii Biosciences and GlaxoSmithKline.[2][3][5]
Headquartered in Cambridge, MA, with facilities in Ottawa, Canada, and Rehovot, Israel, VBI focuses on high-burden diseases like hepatitis B, CMV, EBV, and aggressive cancers, positioning itself to expand commercialization of PreHevbrio while advancing Phase I/II trials for novel therapies.[1][2][6]
VBI Vaccines traces its roots to SciVac Therapeutics Inc., founded prior to 2016, when it rebranded to VBI Vaccines Inc. in May 2016 to reflect its expanded focus on advanced virus-like particle technologies.[3] The company emerged from early work on hepatitis B vaccines, launching Sci-B-Vac as its foundational prophylactic product, approved in Israel and other markets outside the U.S., which demonstrated strong immunogenicity through its unique 3-antigen formulation.[3][5][7] Key pivots included acquiring eVLP platform technology, enabling development of next-generation vaccines that better mimic viruses for superior B- and T-cell responses, and expanding into immunotherapeutics amid rising needs for coronavirus and oncology solutions.[1][3][4]
Early traction came from partnerships, such as with the National Research Council of Canada for pan-coronavirus vaccines and collaborations with Brii Biosciences on VBI-2601 for chronic HBV, alongside pivotal moments like completing Phase III trials for PreHevbrio and securing FDA approval in November 2021.[2][3][5] This evolution humanizes VBI as a nimble biotech leveraging immunology expertise to tackle persistent global health threats.
VBI stands out in vaccine development through these key strengths:
VBI rides the wave of next-generation vaccine platforms like VLPs and mRNA hybrids, accelerated by the COVID-19 pandemic's emphasis on rapid, broad-spectrum immunogens and supply chain resilience.[1][2][5] Timing is critical amid rising antimicrobial resistance, aging populations vulnerable to CMV and HBV, and persistent coronavirus threats, where traditional vaccines fall short on durability and coverage.[2][3][6] Market forces favoring VBI include regulatory nods for differentiated products like PreHevbrio, global demand for thermostable solutions in low-resource settings, and immuno-oncology growth for cancers like glioblastoma.[1][5]
VBI influences the ecosystem by licensing platforms to big pharma, contributing to pan-coronavirus efforts via CEPI, and pioneering functional cures for chronic infections, helping shift vaccines from reactive to proactive immune powerhouses.[3][5]
VBI's trajectory hinges on scaling PreHevbrio commercialization across approved markets while advancing mid-stage trials for VBI-2601 (chronic HBV), VBI-1901 (GBM), and coronavirus candidates, potentially unlocking blockbuster potential in high-prevalence diseases.[2][5][6] Trends like mRNA-VLP convergence, AI-driven antigen design, and global health equity will propel its thermostable innovations, with partnerships mitigating biotech funding risks. Influence may evolve from niche innovator to key player in infectious disease consortia if Phase II data impress, circling back to its core mission: harnessing immunology without limitations to protect underserved populations.[1][2]
VBI Vaccines has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series A in January 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2007 | $36.0M Series A | 5AM Ventures, ARCH Venture Partners |